Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells

Patrick J. Brennan, Rebecca E. Saunders, Mary Spanou, Sarah E. Singleton, M. Teresa Serafini, Liang Sun, Guillaume Heger, Agnieszka Konopacka, Ryan Beveridge, C. Richard Taylor, Peter DePaola, Laurie Gordon, Shenaz B. Bunally, Aurore Saudemont, Andrew B. Benowitz, C. Martinez-Fleites, Danielle L. Schmitt, Robert Damoiseaux, Markus A. Queisser, Heeseon An, Charlotte M. Deane, Michael M. Hann, Lewis L. Brayshaw, Stuart J. ConwayACS 2025 · DOI

TL;DR

Researchers have developed a new "bump-and-hole" molecular system that precisely targets and degrades specific proteins within cells. This breakthrough overcomes a major limitation of existing protein degradation technologies, offering a highly selective tool for drug discovery and biological research.

What Problem Does This Paper Address?

Targeted protein degradation is a powerful approach in drug discovery and basic research, allowing scientists to eliminate disease-causing proteins. A common strategy involves using small molecules called immunomodulatory imide drugs (IMiDs) to recruit a cell's natural protein disposal machinery (the proteasome) to a protein of interest (POI). These IMiDs typically bind to a protein called cereblon (CRBN), which then acts as an adaptor to link the POI to the proteasome.

However, a significant challenge with current IMiDs is their lack of specificity. They often degrade not only the intended POI but also several other naturally occurring proteins (neosubstrates) that share a similar structural motif, such as zinc fingers (ZFs). This off-target degradation can lead to unwanted side effects and complicate the interpretation of experimental results. The authors aimed to create an IMiD-based system that could selectively degrade a POI without affecting these endogenous neosubstrates.

Methods

The core of this work is the "bump-and-hole" strategy, a concept borrowed from medicinal chemistry. The idea is to create a modified target (the "hole") that can only be recognized by a modified drug (the "bump").

  1. Mutagenesis and Screening: The researchers started by identifying key residues in the ZF degron motif of IKZF3 (a known IMiD neosubstrate) that interact with the CRBN-IMiD complex. They then created a large library of over 8,000 mutant ZF degrons. Simultaneously, they synthesized a library of modified IMiD molecules, aiming to create "bumped" versions that would preferentially bind to these mutant ZFs.
  2. Cell-Based Assays: Jurkat cells were engineered to express these mutant ZF degrons fused to a reporter protein (EGFP). These cells were then treated with various IMiD analogues. Degradation was assessed using ratiometric flow cytometry, where the ratio of EGFP to a reference fluorescent protein (mCherry) indicated the extent of degradation.
  3. Library Screening: A high-throughput screening approach was employed. Jurkat cells expressing the library of mutant ZF degrons were treated with selected IMiD compounds. Cells showing degradation (low EGFP signal) were sorted, and their DNA was sequenced to identify which mutant ZF sequences were preferentially degraded by specific IMiD analogues.
  4. Proteomics: To confirm the selectivity of the most promising IMiD-degron pair, quantitative proteomics (TMTpro mass spectrometry) was performed on cells treated with the selected compound. This allowed for a global assessment of protein degradation across thousands of cellular proteins, including known IMiD neosubstrates.
  5. POI Degradation: The validated orthogonal IMiD-degron system was then tested on various proteins of interest (POIs), including TRIM28, CDK9, HPRT1, and NanoLuc, fused to the optimized degron. Degradation was confirmed using Western blotting and luminescence assays.

Datasets

  • ZF Mutant Library: A library of 8,380 mutant zinc finger (ZF) degron sequences was designed and synthesized.
  • IMiD Analogue Library: A library of 36 modified IMiD analogues was synthesized.
  • Cell Lines: Jurkat cells (a T-cell leukemia line), embryonic stem cells (ESCs), and MM.1S cells (a multiple myeloma line) were used for proteomic analysis. HEK293T cells were used for testing degradation of various POIs.
  • Proteomics Data: Quantitative proteomics data from Jurkat, ESC, and MM.1S cells treated with compound 23 and other IMiDs were generated.

Key Insights and Ideas

  • The "Bump-and-Hole" Strategy Works for IMiDs: The study successfully demonstrates that the bump-and-hole principle, previously applied to other molecular systems, can be effectively adapted to create orthogonal IMiD-degron pairs. This opens up new avenues for designing highly specific protein degraders.
  • Targeted Mutations Enhance Selectivity: By carefully mutating specific residues within the ZF degron, the researchers created a "hole" that could be specifically recognized by a "bumped" IMiD analogue. This mutation-based approach is key to achieving selectivity.
  • A Single Mutation Can Confer Significant Selectivity: The Q147A mutation in the ZF degron, when paired with a specific IMiD analogue (compound 19), showed improved degradation of the mutant degron compared to the wild-type. This highlights how even subtle changes can dramatically alter molecular interactions.
  • Optimized Degron-IMiD Pair Achieves High Selectivity: The WEIS degron combined with compound 23 demonstrated remarkable selectivity, degrading the target protein efficiently while leaving endogenous neosubstrates like IKZF1, IKZF3, and SALL4 untouched. This is a significant improvement over traditional IMiDs.
  • Small Degron Tags are Advantageous: The developed degron motif is small (around 7 kDa), which is advantageous for genetic engineering (e.g., CRISPR knock-in) and minimizes potential interference with the POI's function.

Key Results

  • A library of 8,380 ZF mutants and 36 IMiD analogues was screened.
  • The WEIS degron, in combination with compound 23, demonstrated 35-fold selectivity over the wild-type ZF degron.
  • Proteomics studies confirmed that compound 23 with the WEIS degron did not induce significant degradation of any proteins in Jurkat, ESC, or MM.1S cells, whereas pomalidomide degraded numerous endogenous proteins.
  • The system was successfully applied to degrade various POIs, including TRIM28, CDK9, HPRT1, and NanoLuc, with degradation observed at nanomolar concentrations.
  • Degradation kinetics showed rapid protein depletion, with optimal degradation occurring within hours.

Limitations and Future Work

  • Mouse Cereblon Compatibility: The current system is not optimized for mouse cells due to a key mutation in mouse cereblon that hinders IMiD binding. Future work could involve introducing mutations to the degron to improve compatibility with mouse cereblon for in vivo studies.
  • Degron/Linker Optimization: While effective, the authors note that further optimization of the degron sequence, linker length, and attachment site (N- or C-terminus) could potentially enhance degradation efficiency and potency.
  • Structural Confirmation: While docking studies provided insights into the molecular interactions, experimental structural determination (e.g., cryo-EM or X-ray crystallography) of the ternary complexes is needed for definitive confirmation.
  • Regulatory Approval: The use of compound 23 in therapeutic applications would require regulatory approval.

The authors anticipate that this orthogonal IMiD-degron system will be a valuable tool for target validation and drug discovery, offering a highly selective and controllable method for protein degradation.

Summary updated

Abstract

Immunomodulatory imide drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide, can be used to induce degradation of a protein of interest that is fused to a short degron motif, which often comprises a zinc finger (ZF). These IMiDs, however, also induce the degradation of endogenous ZF-containing neosubstrates, including IKZF1, IKZF3, and SALL4. To improve degradation selectivity, we took a bump-and-hole approach to design and screen bumped IMiD analogues against 8380 ZF mutants. This yielded a bumped IMiD analogue that induces efficient degradation of a mutant ZF degron, while not affecting other cellular proteins, including IKZF1, IKZF3, and SALL4. In proof-of-concept studies, this system was applied to induce degradation of the optimum degron fused to CDK9, HPRT1, NanoLuc, or TRIM28. We anticipate that this system will be a valuable addition to the current arsenal of degron systems for use in target validation.
BibTeX
@inproceedings{brennan2025orthogonal,
  author = {Patrick J. Brennan and Rebecca E. Saunders and Mary Spanou and Sarah E. Singleton and M. Teresa Serafini and Liang Sun and Guillaume Heger and Agnieszka Konopacka and Ryan Beveridge and C. Richard Taylor and Peter DePaola and Laurie Gordon and Shenaz B. Bunally and Aurore Saudemont and Andrew B. Benowitz and C. Martinez-Fleites and Danielle L. Schmitt and Robert Damoiseaux and Markus A. Queisser and Heeseon An and Charlotte M. Deane and Michael M. Hann and Lewis L. Brayshaw and Stuart J. Conway},
  title = {{Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells}},
  booktitle = {ACS},
  year = {2025},
  doi = {10.1021/acschembio.5c00751},
}
Figure